Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
Mobina Nakhaei, Researcher in Hematology and Transfusion Medicine and Member of the Educational Development Center at Tarbiat Modares University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Annals of Hematology, adding:
“Why Do Thalassemia Patients Still Develop Alloantibodies Despite ABO/Rh Matching?
A question we addressed in our study on transfusion‑dependent β‑thalassemia patients in Eastern Iran.
Our findings, published in Annals of Hematology (Springer), highlight the ongoing challenge of red blood cell alloimmunization – even with standard ABO and Rh matching.
What we found:
- 74 patients (50% male, 50% female) from South Khorasan
- Alloimmunization prevalence: 9.5%
- 16 alloantibodies identified
- Most common: anti‑K (43.75%) and anti‑E (43.75%)
- Followed by anti‑C (12.5%)
- Blood group O was the most frequent phenotype (39.2%)
- Rh antigens c and e: present in 94.6%
- No significant association with age, sex, blood group, or splenectomy
The takeaway:
To improve transfusion safety, we need to go beyond ABO/Rh – extended matching for Kell and Rh systems, combined with regular antibody screening, is essential in high‑risk populations.
Grateful to my supervisor Fatemeh Mezginejad and my colleague for their collaboration on this work.”
Title: Red blood cell alloimmunization in transfusion-dependent β-thalassemia major patients in Eastern Iran
Authors: Mobina Nakhaei Shamahmood, Mohammad Reza Meghdadi, Maziar Nasiri, Mohammad Javad Yousefi, Fatemeh Mezginejad
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins
-
Jun 27, 2026, 14:01Francesca Palandri: Highlighting Innovation in Rare Disease Care at EHA 2026
-
Jun 27, 2026, 13:51Mubariz Ahsan: Trends in Stroke Mortality in Peripheral Artery Disease from CDC WONDER Study
-
Jun 27, 2026, 13:40Naveen Pemmaraju: Pacritinib Versus Momelotinib in Thrombocytopenic Myelofibrosis
-
Jun 27, 2026, 13:27Limited-Time Open Access for the EAHAD 2026 Joint Session with ISTH – EAHAD
-
Jun 27, 2026, 13:16Stefano Rivella: Stress Erythropoiesis and the Role of HRG1-Mediated Heme Import
-
Jun 27, 2026, 13:10Yahya Samadi: Luspatercept Shows Promise in Reducing Transfusion Burden in β-Thalassemia
-
Jun 27, 2026, 13:03Margarida Marreiros: Supporting Excellence in Hemostasis Testing